Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
All News
Article
Article
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Article
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
Article
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Janet Pope
Tweet
#Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger https://t.co/JHQHu91tud
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies.
https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
David Liew
Tweet
Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco.
Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
David Liew
Tweet
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
Janet Pope
Tweet
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Bella Mehta
Tweet
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Bella Mehta
Tweet
Abatacept in pts at risk of #RA data from clinical trial.
213 pts, 31 centers.
Pts with multiple autoantibodies improved the most with abatacept.
@rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Bella Mehta
Tweet
Denosumab in hand OA prevented erosions!
#eular2023 @RheumNow https://t.co/Ij2CVjh1ET
Aurelie Najm
Tweet
Treat early it is also cheaper!
5 yr cost of RA ttmt
€11250 ACPA+ > €3526 ACPA-
bDMARDS users
€44788 ACPA+ > €40896 ACPA-
ACPA- "late" ttmt 46% more expensive
ACPA+ early vs. late = similar costs
@Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs.
OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Aurelie Najm
Tweet
Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE?
DANBIO study (>1,300 pts w/ IA)
Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5)
Decrease 15% GP2017 switchers
#EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0
Bella Mehta
Tweet
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
David Liew
Tweet
The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations
“A little bit of a paradigm shift here” - Laure Gossec
2023 @eular_org recommendations
#EULAR2023 @RheumNow https://t.co/gr9IOg1bbj
David Liew
Tweet
Which bDMARD first in PsA?
2023 @eular_org recommendation: no preferred order. All are equal in its eyes
#EULAR2023 @RheumNow https://t.co/6HNNamAj1J
Aurelie Najm
Tweet
How do we improve MTX adherence?
Biochemical measure of MTX adherence
37% of patients starting a biologic do not take their MTX (!)
Those who do respond better to first Biologic at 6 Mo than those who don’t
37% biologic responders = non adherent
POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj
Janet Pope
Tweet
A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q
